Silence Therapeutics PLC (SLN) - Total Assets
Based on the latest financial reports, Silence Therapeutics PLC (SLN) holds total assets worth $146.79 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore Silence Therapeutics PLC (SLN) debt coverage ratio to assess how comfortably operating cash covers total debt obligations.
Silence Therapeutics PLC - Total Assets Trend (1995–2024)
This chart illustrates how Silence Therapeutics PLC's total assets have evolved over time, based on quarterly financial data. See Silence Therapeutics PLC shareholders equity for net asset value and shareholders' equity analysis.
Silence Therapeutics PLC - Asset Composition Analysis
Current Asset Composition (December 2024)
Silence Therapeutics PLC's total assets of $146.79 Million consist of 92.5% current assets and 7.5% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 59.9% |
| Accounts Receivable | $26.91 Million | 13.3% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $312.00K | 0.2% |
| Goodwill | $9.39 Million | 4.6% |
Asset Composition Trend (1995–2024)
This chart illustrates how Silence Therapeutics PLC's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market cap of Silence Therapeutics PLC.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Silence Therapeutics PLC's current assets represent 92.5% of total assets in 2024, a decrease from 99.9% in 1995.
- Cash Position: Cash and equivalents constituted 59.9% of total assets in 2024, up from 41.0% in 1995.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 4.0% of total assets, an increase from 0.0% in 1995.
- Asset Diversification: The largest asset category is accounts receivable at 13.3% of total assets.
Silence Therapeutics PLC Competitors by Total Assets
Key competitors of Silence Therapeutics PLC based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Genfit S.A.
PA:GNFT
|
France | €157.93 Million |
|
Hyundai Bioscience Co. Ltd
KQ:048410
|
Korea | ₩129.10 Billion |
|
Altimmune Inc
NASDAQ:ALT
|
USA | $279.93 Million |
|
Clarity Pharmaceuticals Ltd
AU:CU6
|
Australia | AU$255.67 Million |
|
Jiangsu GDK Biotechnology Co Ltd
SHG:688670
|
China | CN¥1.48 Billion |
Silence Therapeutics PLC - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 7.69 | 9.31 | 2.99 |
| Quick Ratio | 7.69 | 9.31 | 3.91 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $116.25 Million | $140.60 Million | $50.82 Million |
Silence Therapeutics PLC - Advanced Valuation Insights
This section examines the relationship between Silence Therapeutics PLC's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.84 |
| Latest Market Cap to Assets Ratio | 1.61 |
| Asset Growth Rate (YoY) | 69.6% |
| Total Assets | $202.63 Million |
| Market Capitalization | $326.86 Million USD |
Valuation Analysis
Above Book Valuation: The market values Silence Therapeutics PLC's assets above their book value (1.61x), reflecting positive investor sentiment about the company's future prospects.
Rapid Asset Growth: Silence Therapeutics PLC's assets grew by 69.6% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Silence Therapeutics PLC (1995–2024)
The table below shows the annual total assets of Silence Therapeutics PLC from 1995 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $202.63 Million | +69.64% |
| 2023-12-31 | $119.45 Million | +11.11% |
| 2022-12-31 | $107.50 Million | +11.75% |
| 2021-12-31 | $96.19 Million | +11.89% |
| 2020-12-31 | $85.97 Million | +86.58% |
| 2019-12-31 | $46.08 Million | +18.50% |
| 2018-12-31 | $38.88 Million | -29.31% |
| 2017-12-31 | $55.01 Million | -1.41% |
| 2016-12-31 | $55.79 Million | -9.34% |
| 2015-12-31 | $61.55 Million | +106.73% |
| 2014-12-31 | $29.77 Million | +1.61% |
| 2013-12-31 | $29.30 Million | +71.60% |
| 2012-12-31 | $17.07 Million | -48.94% |
| 2011-12-31 | $33.44 Million | -1.53% |
| 2010-12-31 | $33.96 Million | +208.86% |
| 2009-12-31 | $10.99 Million | -23.54% |
| 2008-12-31 | $14.38 Million | -26.18% |
| 2007-12-31 | $19.48 Million | +16.28% |
| 2006-12-31 | $16.75 Million | -2.45% |
| 2005-12-31 | $17.17 Million | +438.31% |
| 2004-12-31 | $3.19 Million | -50.84% |
| 2003-12-31 | $6.49 Million | -23.57% |
| 2002-12-31 | $8.49 Million | -12.20% |
| 2001-12-31 | $9.67 Million | -20.10% |
| 2000-12-31 | $12.10 Million | +11.95% |
| 1999-12-31 | $10.81 Million | +173.90% |
| 1998-12-31 | $3.95 Million | -25.16% |
| 1997-12-31 | $5.27 Million | -22.51% |
| 1996-12-31 | $6.81 Million | +122.27% |
| 1995-12-31 | $3.06 Million | -- |
About Silence Therapeutics PLC
Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Zerlasiran (SLN360), which is in Phase II clinical trial for cardiovascular disease associated with elevated … Read more